

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

PFIZER INC.,)
GLOBAL BLOOD THERAPEUTICS, INC.)
and PF PRISM IMB B.V.,)
)
Plaintiffs,)
)
v.) C.A. No. _____
)
MSN LABORATORIES PRIVATE LTD. and)
MSN PHARMACEUTICALS INC.,)
)
Defendants.)

**SUPPLEMENTAL INFORMATION FOR PATENT CASES
INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)**

Plaintiffs hereby provide the information below with respect to the deadlines set for in
21 U.S.C. 355(j):

Date Patentee(s) Received Notice: January 25, 2024
Date of Expiration of Patent: See Below*
30-Month Stay Deadline: May 25, 2027**

* U.S. Patent Nos. 9,447,071; 10,722,502; and 11,452,720 expire on February 6, 2035; U.S. Patent No. 10,493,035 expires on October 12, 2037; and U.S. Patent No. 11,020,382 expires on December 2, 2036.

** This deadline is calculated pursuant to New Chemical Entity status.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Megan E. Dellinger

OF COUNSEL:

Dimitrios T. Drivas
Amit H. Thakore
Joel L. Broussard
WHITE & CASE LLP
1221 Avenue of the Americas
New York, NY 10020
(212) 819-8200

March 8, 2024

Jack B. Blumenfeld (#1014)
Megan E. Dellinger (#5739)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisonichols.com
mdellinger@morrisonichols.com

*Attorneys for Plaintiffs Pfizer Inc.,
Global Blood Therapeutics, Inc. and
PF PRISM IMB B.V.*